Today we announced that the European Commission has granted marketing authorization for the updated formulation of our COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months https://t.co/bWeRXEugP6

Tag-uri: Coronavirus